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Introduction
Ligament and tendon repair involves a complex series of coordinated events orchestrated by various cell types, cytokines and
other factors. The repair process extends months to years and results in scar tissue mechanically inferior to native tissue. This
is in clear contrast to tissue "regeneration" which would recapitulate the native tissue. Numerous approaches to stimulate a
regenerative scenario have been attempted, including tissue-engineering, non-steroidal anti-inflammatories, ultrasonic, or
electrical stimulation, but none have resulted in complete regeneration. In pursuit of a more regenerative outcome, it is
important to understand the fundamentals of the normal healing process. Previous work from our lab identified a number of
cellular, vascular, and molecular components integral to early healing [1]-[3]. Specifically, macrophages within the injured
ligament peaked between day 3 and 5, while blood vessels primarily appeared between day 7 and 11 post-injury. The change
in macrophage infiltration and angiogenesis during healing is modulated by the interleukin environment. Macrophages provide
an ongoing source of cytokines, including IL-1[alpha], IL-1[beta], IL-6, and TNF-[alpha], and are responsible for modulating
inflammatory cell adhesion and migration as well as fibroblast proliferation. [4] Ablation of macrophage-produced cytokines
subsequently results in decreased fibroblast proliferation and ECM deposition. Consequently, ablation of macrophage-
produced cytokines impedes healing and delays functional recovery. [5] Therefore, identifying the interleukins specific to
ligament injury during peak macrophage activation and angiogenesis may elucidate the inflammatory mechanisms and
subsequent scar formation.
In response to signals derived from damaged tissue and interleukins, monocytes/macrophages undergo reprogramming which
leads to the emergence of macrophage subgroups with distinct phenotypes. Two broad subsets include the M1 (classically
activated) and the resident M2 (further divided into the M2a, b, and c groups) macrophages. After injury, monocytes are
recruited, enter the damaged tissue and differentiate into M1 mononuclear phagocytes. These newly recruited cells secrete
pro-inflammatory mediators, such as IL-1, and participate in activation of various cytotoxic processes, including the respiratory
burst, which creates extensive collateral damage.[6]-[8] An excessive M1 macrophage response may lead to aberrant
inflammation and extensive collateral damage. In contrast to the M1 inflammatory macrophages, the M2 macrophages exhibit
potent anti-inflammatory activity and may play important roles in wound healing and fibrosis. [9], [10] The M2 macrophages
antagonize the M1 macrophage response, which may be pertinent for the activation of the wound healing and for restoration of
tissue homeostasis. Recent studies have indicated that M1 macrophages can be converted into anti-inflammatory
macrophages with a M2 wound-healing phenotype. [11], [12] M2 macrophages can then produce factors that induce
myofibroblast apoptosis, serve as antigen presenting cells, and decrease the magnitude and duration of inflammation to
promote wound healing.
The current study was undertaken to identify interleukins involved during peak macrophage up-regulation and angiogenesis
during early ligament healing using microarray analysis. Based on preliminary microarray results, we hypothesized that
blocking IL-1 activity via IL-1Ra administration would modulate the macrophage response during early healing to reduce
fibrosis and scarring.
Materials and Methods
Normal MCL Healing Model
All procedures were approved by the University of Wisconsin Institutional Animal Care and Use Committee. All surgeries were
performed using isofluorane, and all efforts were made to minimize suffering. Twenty-seven skeletally mature male Wistar rats
(275-299 g) were used as an animal model to study normal MCL healing after surgical transection. A transected rather than
torn MCL was used as an experimental model to create a uniform defect for healing. Rats (n = 18) were anesthetized via
isofluorane and subjected to bilateral MCL transection. A 1 cm skin incision was made over the medial aspect the left and right
stifles, exposing the sartorius muscle and underlying MCL. The mid-point of the MCL was completely transected and the
muscular, subcutaneous and subdermal tissue layers were each closed with 4-0 Dexon suture. Animals were allowed
unrestricted cage movement immediately after surgery. Another group of 9 animals did not undergo surgery and served as
intact controls. At 3 and 7 days post-injury (n = 9/day), MCLs were snap-frozen and used for microarray analysis.
Microarray Analysis
In order to identify interleukins regulated during peak macrophage and angiogenesis infiltration, MCLs (n = 9/day) were
collected at day 3 and 7 post-injury and compared to interleukin expression of the intact MCL (n = 9) using microarray analysis.
Tissue was processed as previously reported. [1] Briefly, snap-frozen MCLs were homogenized in Trizol and total RNA was
isolated via column fractionalization using the RNeasy Total RNA kit (Qiagen, Valencia, CA). The quality and quantity of each
RNA sample was analyzed on the Agilent 2100 BioAnalyzer using the RNA6000 NanoChip and the NanoDrop 1000
Spectrophotometer (Thermo Scientific, Wilmington, USA), respectively. Total RNA was transcribed to cDNA using an oligo dT
primer containing the T7 RNA polymerase promoter. Microarray hybridization was performed by the University of Wisconsin
Biotechnology Gene Expression Center (Madison, WI). Double stranded cDNA was purified and biotin-labeled in accordance
with the Affymetrix gene analysis protocol (Affymetrix, Santa Clara, CA). cRNA was fragmented at 0.5 [micro]g/[micro]l final
concentration and the size range of the cRNA before (0.1 kb and longer) and after (35-200 base fragments) was checked by
agarose gel electrophoresis. The Affymetrix Rat 2.0 Genome GeneChips (Affymetrix, Santa Clara, CA) containing over 31,000
probe sets and representing 28,700 rat genes were used. A total of 9 chips were hybridized using 3 biological triplicates
(containing 3 ligaments per sample) at 3 time points (intact, day 3 and day 7). GeneChips® (Affymetrix, Santa Clara, CA) were
hybridized with biotin labeled ds-cDNA for 16 hours at 45°C. Following hybridization, the labeled samples were washed and
exposed to streptavidin-phycoerythrin. Quantification of GeneChips was performed by Affymetrix GeneChip Operating
Software (AGCC version 2.0). Microarray data were log transformed [log (base 2)] and the log ratio between the intact ligament
with day 3 or day 7 was calculated and expressed as fold change. A gene was considered up or down regulated if the day 3 or
day 7 samples were at least 2 fold different than the intact controls. Batch results were submitted to the Gene Expression
Omnibus (GEO) repository (Accession number:GSE47676). For summary of microarray results not pertaining to the
interleukins, refer to Chamberlain, et al., 2011. [1].
IL-1Ra Experimental Model
In order to identify the influence of IL-Ra on MCL healing, 22 rats were randomly divided into 2 groups (n = 11 rats/treatment)
and subjected to bilateral MCL transection (as described above). Treatment regime was based on previously published reports.
[13] Thirty minutes prior to surgery, animals were administered 6.25 ng/ul IL-1Ra or PBS i.p. (IL-1Ra diluent; control)
immediately before surgery and 3 hours post-surgery. At 5 and 11 days post-injury (n = 3 rats/trt/day) MCLs were measured for
length, collected, and weighed; ipsilateral MCLs were used for histology/immunohistochemistry and contralateral MCLs for
ELISA. Ligaments used for immunohistochemistry (IHC) were carefully dissected and immediately embedded longitudinally, in
optimal cutting temperature (O.C.T.) medium for flash freezing. Tissue used for multiplex analysis was immediately snap-
frozen. An additional set of MCLs were collected at day 11 (n = 5 rats/trt) and used for mechanical testing. Mechanical testing
was not performed on day 5 because the ligaments were too structurally compromised for meaningful data with our testing
method. Animals used for mechanical testing, were sacrificed and limbs were stored in toto at -70 C until used.
on day 5 and 11 MCLs. Longitudinal cryosections were cut at a 5 [micro]m thickness, mounted on Colorfrost Plus microscope
slides and maintained at -70 C. IHC was performed on frozen sections using mouse monoclonal or rabbit polyclonal antibodies.
Cryosections were fixed in acetone, exposed to 3% hydrogen peroxide to eliminate endogenous peroxidase activity, blocked
with Background Buster (Innovex Biosciences, Richmond, CA) and incubated with rabbit or mouse primary antibodies.
Sections were then incubated with biotin, and streptavidin-conjugated to horseradish peroxidase using the Stat Q staining kit
(Innovex Biosciences, Richmond, CA). The bound antibody complex was visualized using diaminobenzidine (DAB). Stained
sections were dehydrated, cleared, cover-slipped and viewed using light microscopy.
Mouse monoclonal antibodies to CD68 (1:100, Abcam-Serotec, Raleigh, NC), CD163 (1:100, Abcam-Serotec, Raleigh, NC),
CD31 (1:100, Abcam-Serotec, Raleigh, NC), [alpha]-smooth muscle actin (SMA; no dilution, Abcam-Serotec, Raleigh, NC), and
Ki-67 (1:100, Dako, Carpinteria, CA) were utilized to identify the classically activated macrophages (M1), alternatively activated
macrophages (M2), endothelial cells, myofibroblasts and proliferating cells. To identify type I procollagen (straight; SP1.D8;
Developmental Hybridoma, Iowa City, Iowa) and type III collagen (1:8000, Sigma-Aldrich, St. Louis, MO) mouse antibodies
were used.
After IHC staining, micrographs were collected using a camera assisted microscope (Nikon Eclipse microscope, model E6000
with an Olympus camera, model DP79). Within each stained tissue section, three images were captured within the granulation
tissue (granulation tissue proximal edge, granulation tissue distal edge, center of granulation tissue), two images were captured
away from the granulation tissue (proximal end and distal end of the MCL), and one image was captured within the
epiligament. Two to three sections were counted per animal. Images captured for measurement of granulation tissue size,
endothelial cells, myofibroblasts, type I procollagen, and type III collagen were quantified via Image J (NIH). Images of blood
vessel lumen, proliferating cells, and M1 and M2 macrophages were quantified manually.
Histology
Ligament cryosections were H&E stained to observe general morphology of the healing ligaments. After staining, images were
captured and the granulation tissue regions were measured using Image J (National Institutes of Health, NIH). Granulation
tissue area was normalized to the total MCL area and expressed as the percent normalized granulation tissue.
Multiplex Assay
To identify the influence of IL-1Ra on MCL cytokine production, a rat 10-plex Luminex assay (Life Technologies, Grand Island,
NY) was performed using day 5 and 11 MCLs. MCLs were washed in Cell Wash Buffer (Bio-Rad, Hercules, CA) placed in Navy
Bead Lysis Kit tubes containing a 0.9-2.0 mm stainless steel bead blend, 3.2 mm stainless steel balls (Next Advance, Averill
Park, NY) and Lysing Solution (Bio-Rad, Hercules, CA). Samples were homogenized via Bullet Blender (Next Advance, Averill
Park, NY) for 10 min. Supernatant was collected and used for BCA (to determine total protein concentration) and subsequent
Multiplex analysis. Multiplex cytokine assays (Life Technologies, Grand Island, NY) were performed according to the
manufactures instructions. Diluted capture bead solution was vortexed, sonicated and added to each well. Standards, samples,
spleen (serving as positive control), and lysis buffer (serving as negative control) were added to the wells and incubated in the
dark, overnight at 4 C on a plate shaker. The next day, samples were washed, incubated with biotinylated detector antibody,
and streptavidin-RPE solution. After washing and re-suspension in working wash solution, samples were read on a Luminex
200 instrument (Luminex, Austin TX). Ten proteins were included in the platform, including IL-1[alpha], IL-1[beta], interleukin-10
(IL-10), interleukin-2 (IL-2), interleukin-12 (IL-12), interleukin-4 (IL-4), interleukin-6 (IL-6), tumor necrosis factor-[alpha] (TNF-
[alpha]), interferon-[gamma] (IFN-[gamma]), and granulocyte macrophage-colony stimulating factor (GM-CSF). Assessment of
the Lumenix assay was performed by verifying each standard curve point was within 80-120% recovery, and 2 standard
deviations above background. Cytokine concentrations were normalized to protein concentration and expressed as ng/mg.
Mechanical Testing
In order to test the functional mechanical properties of the healing MCL after IL-1Ra treatment, day 11 ligaments were
mechanically tested. Pull-to-failure testing was performed as previously described by Provenzano et al. 14-16 After sacrifice the
MCL was removed with both femoral and tibial insertion sites and the surrounding tissue was carefully excised with special
care taken to avoid damaging the insertion sites. During preparation, the femur-MCL-tibia (FMT) complex was kept hydrated
using PBS. The width and thickness of the ligament was measured optically and the cross-sectional area for the ligament was
estimated assuming an elliptical cross section. The FMT complex was mounted in a custom made testing bath and mechanical
testing machine. Optical markers were applied to the ligament on the insertion sites and the displacement was recorded
optically. The ligament was pre-loaded to 0.1 N and subsequently preconditioned (cyclically loaded to 1% strain for 10 cycles).
Dimension measurements for the ligament were recorded at the pre-load. The ligament was then pulled to failure at a rate of
10% strain per second. Failure force was recorded as the highest load prior to failure of the ligament and failure stress was
calculated by dividing the failure force by the initial cross-sectional area of the ligament. The slope of the linear portion of the
line relating stress to elongation was used to calculate a normalized stiffness parameter.
In order to identify cellular and ECM changes within the healing MCL after IL-1Ra treatment, IHC and histology were performed
Statistical Analysis
Microarray data were analyzed using the two-sample Welch t-test to determine significance per gene. To minimize the false
discovery rate, the Storey q-value method was performed and significance was based on q <.01. Any Q-value less than or
equal to 0.01 per gene was considered significant. Paired t-tests were used to evaluate differences between intact and day 3,
intact and day 7, or day 3 and day 7. A critical value of.05 was considered as the criterion to select a significant fold change in
gene expression between days. Data are presented as fold change of the means of day 3 and day 7 from the intact ligament
values (fold change ± S.D.). For the IHC results MCL regions were subgrouped (granulation tissue, outside of granulation
tissue, and total MCL) to identify any spatial differences of each factor measured. A one-way analysis of variance (ANOVA)
was then used to examine treatment and/or day differences for the IHC data, as well as the multiplex and mechanical data. If
the overall p-value for the F-test in ANOVA was significant, post-hoc comparisons were performed using the Fisher's LSD
method. Experimental data are presented as the means ± S.E.M. All p-values reported are two sided. P<0.05 was used as the
criterion for statistical significance. Computations and figures were performed using KaleidaGraph, version 4.03 (Synergy
Software, Inc., Reading, PA).
Results
Microarray Results to Identify Interleukins (Il)
Normal healing of the MCL 3 and 7 days post-injury resulted in significant modulation of 12 MCL-derived interleukins (Fig. 1;
Table 1). Of those Il s, six resulted in a 2 fold or greater difference from the intact MCL at day 3, three at day 7, and three on
both day 3 and day 7. Interleukin-1 receptor like-1 (Il1rl1 ) was the most prevalent interleukin up-regulated on both day 3 and 7.
Il11 and Il16 were also significantly up- and down-regulated, respectively, on both days. Interleukins up-regulated at day 3
included Il1b, Il1rn, Il6, Il7, Il17r, and Il18 (no interleukins were down regulated at day 3). Those ILs regulated at day 7
included Il11ra1 , Il13ra1, and Il15 . These results indicate that interleukins with a predominantly pro-inflammatory role play an
active role during early normal ligament healing. Based on the time of MCL collection at 3 and 7 days, most of the interleukins
likely originate from the macrophages.
Figure 1. Microarray results identifying specific interleukins modulated at days 3 and/or 7 post-injury. A total of 12
interleukins were significantly modulated (2 fold greater than normal and q-value <.05) compared to the intact control. Of those
12, 6 were up-regulated at day 3 only (il6, il7, il17r, 1l18, il1b, and il1rn), 1 up-regulated at day 7 only (il13ra1), 1 down-
regulated at day 7 only (il11ra1), 2 up-regulated at both day 3 and 7 (il1rl1, il11), and 1 down-regulated at both day 3 and 7
(il16). Interleukins regulated during healing were both pro- and anti-inflammatory (a). Members of the il1 family were
significantly regulated with healing (b). Microarray data are compared to the normal intact ligament and expressed as fold
change ± S.D. * indicate fold change [greater than or equal to]2 from the intact control. [see PDF for image]
IL-1Ra Injury Model
To further analyze the influence of interleukins on MCL healing IL-1Ra, a protein that binds IL-1 receptor to inhibit IL-1
activation, was administered to a rat MCL injury model. IL-1 was targeted based on its identification via microarray and its
established pro-inflammatory influences in various pathologies. To first determine if IL-1Ra modulated wound healing size,
granulation tissue area from H&E stained MCLs were sectioned and normalized to total MCL area (Figs. 2; 3a-b) indicates no
change in granulation tissue size between PBS (4.86% ±.35) and IL-1Ra (7.57% ±1.07) at day 5. On day 11, IL-1Ra (12.40%
±1.33) significantly increased (p = .021) area of granulation tissue compared to the control (7.83% ±1.92).
Figure 2. Immunohistochemistry results of selected cellular factors regulated by IL-1Ra. Graph of the percent healing
region (a), granulation tissue localized M1 macrophages (b), granulation tissue-localized M2 macrophages (c), M2
macrophages outside the granulation tissue (d), and granulation tissue-localized proliferating cells (d), at 5 and 11 days post-
injury after PBS or IL-1Ra treatment. On day 11, IL-1Ra significantly increased the percent healing region (a). No differences
within the MCL were observed at any other points. Although no differences were observed with M1 macrophages (b), IL-1Ra
treatment increased M2 macrophage numbers at day 5 and/or day 11 within (c) and outside of the granulation tissue (d).
Proliferating cells were significantly reduced at day 5 (e). a, b, c indicates within a graph, bars without a common superscript
letter differ (results of Fisher's LSD post-hoc pairwise analysis, p<.05). Values are expressed as mean cell numbers ± S.E.M.
[see PDF for image]
IHC of Granulation Tissue Factors
Because IL-1 has been demonstrated to stimulate an inflammatory reaction after injury, components of inflammation and
granulation tissue formation were monitored, including the M1 and M2 macrophages, proliferating cells, endothelial cells, blood
vessel lumen, and myofibroblasts. Regardless of treatment, both M1 and M2 macrophages were significantly higher at day 5
than day 11 (Fig. 2). Treatment with IL-1Ra did not significantly change the M1 cell numbers (Fig. 2b). In contrast, treatment
with IL-1Ra significantly increased the granulation tissue-localized M2 macrophages at both day 5 (10.72±1.01 vs 15.04±1.15
cells/mm2 ) and 11(4.39±1.06 vs 7.67±.63 cells/mm2 ) post-injury (Figs. 2c; Fig. 3c-f). M2 macrophages located outside of the
granulation tissue were also significantly increased at day 11 after IL-1Ra treatment (5±1.06 vs 7.83±.63 cells/mm2 ; Fig. 2d).
Immunohistochemistry of proliferating cells indicated a significant increase in cell number at day 5 vs day 11. However,
treatment with IL-1Ra reduced the number of proliferating cells at day 5 (36.96±8.72 vs 25.89±3.07; Figs. 2e; 3g-h). No
significant changes in proliferative cell number were observed outside the granulation tissue or epiligament. Endothelial cells
and blood vessel lumen identified within the granulation tissue were increased in number after IL-1Ra treatment at day 5
whereas no effects were observed on day 11 (Figs. 4a-b; f-g). Similar to the proliferating cells, day 5 myofibroblasts were
decreased with IL-1Ra treatment throughout the entire ligament (2x10-3 ±0.4x10-3 vs 0.8x10-3 ±.2x10-3 ; Fig. 4c, h-i). Results
were not significant at day 11.
Figure 3. Representative micrographs of the healing MCL after PBS or IL-1Ra treatment. Micrographs demonstrate H&E
staining (a-b), and immunohistochemistry of M2 macrophages (c-f), and proliferating cells (g-h) after PBS (left column) or
IL-1Ra (right column) treatment. H&E staining of the day 11 MCL indicating larger granulation tissue size (a-b). M2
macrophages 5 days- (c-d) and 11 days post-injury (e-f) increase in number after IL-1Ra treatment. In contrast, proliferating
cells decrease on day 5 (g-h) after IL-1Ra administration. [see PDF for image]
Figure 4. Immunohistochemistry results of cellular and ECM factors regulated by IL-1Ra. Immunohistochemistry results
showing the effects of PBS and IL-1Ra on granulation tissue localized endothelial cells (a), granulation tissue-localized blood
vessel lumen (b), total myofibroblasts (c), type I procollagen (d), and type III collagen (e) at 5 and 11 days post-injury. IL-1Ra
significantly increased the number of endothelial cells and blood vessel lumen on day 5 (a-b), but not day 11. In contrast,
IL-1Ra significantly decreased the number of myofibroblasts at day 5 (c). No differences within the MCL were observed on day
11 (c). Regardless of day, no treatment differences were observed with type I procollagen (d) and type III collagen (e). ). a, b
indicates within a graph, bars without a common superscript letter differ (results of Fisher's LSD post-hoc pairwise analysis,
p<.05). Values are expressed as mean density ± S.E.M. Representative micrographs of endothelial cells/blood vessel lumen (f-
g) and myofibroblasts (h-i) 5 days post-injury after PBS (left column) and IL-1Ra (right column) treatment. [see PDF for image]
Immunohistochemistry of Collagens
Since a number of granulation tissue localized factors were significantly modified by IL-1Ra, type I procollagen and type III
collagen were measured to determine if any ECM factors were likewise changed during ligament healing. Fig. 4d-e indicates no
significant change in either type I procollagen or type III collagen after IL-1Ra treatment.
Multiplex Results
The previous IHC results identified the cells influenced by IL-1Ra treatment during MCL healing. The next experiments
examined the influence of IL-1Ra on cytokine production by the cells of the MCL. As Figure 5 indicates, IL-1[alpha] (PBS,
0.83±.03 pg/mg vs. IL-1Ra, 3.11±.12 pg/mg; Fig. 5a), but not IL-1[beta] (PBS, 3.92±.22 pg/mg vs. IL-1Ra, 4.12±.12 pg/mg; Fig.
5b), was up-regulated at 5 days post-injury after IL-1Ra treatment, suggesting that IL-1Ra may have blocked IL-1 receptor
activation at day 5, but IL-1 production continued. By day 11, IL-1Ra treatment significantly reduced IL-1[alpha] (PBS, 1.72±.03
pg/mg vs. IL-1Ra, 0.65±.08 pg/mg) and tended (p = .056) to reduce IL-1[beta] (PBS, 1.39±.12 pg/mg vs. IL-1Ra,.97±0.04
pg/mg). On day 5, the pro-inflammatory cytokines, IL-12 (Fig. 5c; PBS, 1.78±0.03 pg/mg vs. IL-1Ra, 0.70±0.02 pg/mg), IL-2
(Fig. 5d; PBS, 0.26±0.02 pg/mg vs. IL-1Ra.20±0.01 pg/mg), and IFN-[gamma] (Fig. 5e; PBS,.47±.01 pg/mg vs. IL-1Ra,.38±.09
pg/mg) were significantly down-regulated by IL-1Ra. On day 11, IL-12 remained down-regulated (PBS, 1.01±0.01 pg/mg vs.
IL-1Ra, 0.63±.02 pg/mg) whereas IL-2 (PBS, 0.14±0 pg/mg vs. IL-1Ra, 0.10±0.04 pg/mg) and IFN- [gamma] (PBS,.21 pg/mg
vs. IL-1Ra,.19±.01 pg/mg) was not significantly different between treatments. Of the anti-inflammatory cytokines measured,
IL-10 was significantly up-regulated by IL-1Ra treatment at day 5 (Fig. 5f; PBS, 0±0.00 pg/mg vs. IL-1Ra, 0.41±0.09 pg/mg),
but not day 11 (PBS, 0.36±.00 pg/mg vs. 0.36±0.01 pg/mg). IL-6 (Fig. 5g) was not significantly different between treatments.
Levels of GM-CSF, TNF-[alpha], and IL-4 were below the detectable sensitivity range.
Figure 5. Luminex results of cytokines regulated by IL-1Ra. Graphs show the effects of PBS and IL-1Ra on MCL-derived
IL-1[alpha] (a), IL-1[beta] (b), IL-12 (c), IL-2 (d), IFN-[gamma] (e) IL-10 (f), and IL-6 (g) production. Blockade of the IL-1
activation resulted in an accumulation of IL-1[alpha] (a) and IL-1[beta] (b). By day 11, inhibition of the IL-1R resulted in a down-
regulation of IL-1[alpha] (a) and tended to decrease IL-1[beta] (b; p = .056). IL-1Ra significantly decreased the pro-
inflammatory cytokines, IL-12 (c), IL-2 (d), and IFN-[gamma] (e) on day 5. IL-12 levels remained significantly different after
IL-1Ra on day 11. The anti-inflammatory cytokine, IL-10 was up-regulated at day 5 after IL-1 inhibition (f). IL-6 was not
significantly influenced by treatment (f). Beneath graph, p value indicates ANOVA results. a, b, c indicates within a graph, bars
without a common superscript letter differ (results of Fisher's LSD post-hoc pairwise analysis, p<.05). *indicates p value.056.
Values are expressed as normalized cytokine concentration (ng cytokine/mg tissue weight) ± S.E.M. [see PDF for image]
Mechanical Testing
To determine if IL-1Ra treatment affected ligament function, the day 11 MCLs (Fig. 6) were mechanically tested. Ligament
failure force, failure stress, and stiffness were measured. No significance difference was found between IL-1Ra-treated
specimens and the PBS control for any parameter tested (p>0.05). These results therefore suggest that IL-1Ra treatment did
not reduce the mechanical properties of the healing ligament or inhibit functional recovery.
Figure 6. Mechanical results of the healing MCL after IL-1Ra treatment. Graphs show failure force (a), stiffness (b), and
failure stress (c) of the MCL 11 days post-injury after PBS or IL-1Ra treatment. No significance was observed in any tested
parameter (p>.05). Results are expressed as mean ± S.E.M. [see PDF for image]
Discussion
This study helps elucidate the role of cytokines in ligament healing. Interleukin expression after injury is a critical regulator of
inflammation, healing and downstream scar formation. The present study identified the interleukins significantly modulated
during MCL healing. Of the interleukins identified, components of the IL-1 family were significantly up-regulated. The impact of
IL-1 was further demonstrated after exogenous administration of IL-1Ra to the injured MCL at the time of surgery to inhibit IL-1
activation. This resulted in decreased pro-inflammatory cytokines (IL-12, IL-2), myofibroblasts, and proliferating cells, as well as
increased anti-inflammatory cytokines (IL-10), endothelial cells/blood vessel lumen, M2 macrophages, and granulation tissue
size. These results support the concept that IL-1Ra modulates some MCL-localized granulation tissue components and
cytokine production to create a transient environment that is less inflammatory. Of note, however, these changes in the
inflammatory cascade did not significantly compromise or improve mechanical outcome, nor did they sustain a more
regenerative healing response.
Microarray analysis of the normal healing MCL revealed significant changes in interleukin expression. Of interest, Il1b and Il1ra
were significantly up-regulated after injury. IL-1 plays a central role in cell growth, tissue repair and chronic inflammatory
diseases, and has emerged as a critical player in inflammation and tissue destruction of arthritis models. [14]-[17] Receptors for
IL-1 are found on the macrophages, fibroblasts, T and B lymphocytes, enabling IL-1[beta] to elicit both an inflammatory and
fibrotic response. Indeed, previous studies have identified IL-1[beta] during both M1-macrophage-predominated inflammation
and myofibroblast/matrix deposition-controlled fibrogenesis [18] The naturally occurring inhibitor to IL-1 is IL-1Ra. IL-1Ra is
able to bind to the IL-1R with similar affinity as IL-1[alpha] and IL-1[beta] and inhibit IL-1 activity. Past reports have indicated
that IL-1Ra suppresses pathologies related to the abnormal increase of IL-1 in rheumatoid arthritis, osteoarthritis, and
intervertebral disc degeneration.[19]-[25] Although IL-1Ra binding affinity to IL-1R is high, a 10-100 molar excess of IL-1Ra is
required to inhibit IL-1 activity. [26], [27] Taken together, the results suggest that excess administration of IL-1Ra in our protocol
should inactivate IL-1 signaling which in turn, should modulate macrophage-stimulated inflammation and/or myofibroblast-
induced fibrosis in our healing MCLs.
The increase in M2 macrophages after IL-1Ra administration suggests that IL-1Ra stimulated macrophage polarization to the
M2 phenotype. A previous report demonstrated fibrotic and macrophage polarization effects using the IL-1 signal transducer,
MyD88, knockout mouse model. [28] MyD88 normally induces an M1 polarization, but a lack of MyD88 altered macrophage
polarization towards an anti-inflammatory M2 phenotype. [28] The current results likewise suggest that inhibition of IL-1
activation induces an M2 macrophage phenotype. The Multiplex data further suggest that IL-1Ra stimulate an anti-
inflammatory response as indicated by the day 5 increase in anti-inflammatory IL-10 and concomitant decrease in pro-
inflammatory IL-2 and IL-12.
IL-1 has been identified as a strong promoter of angiogenesis. [26], [29] However, IL-1inhibition in the current study actually
increased endothelial cells and blood vessel lumen number. This increase may result from the IL-1Ra-induced increase in M2
macrophages. Indeed, IL-1 failed to stimulate an angiogenic response by endothelial cells without the presence of inflammatory
cells, in vitro. [30] Macrophages play an important role in the angiogenic process, by facilitating vascular permeability for
endothelial cell migration and promoting endothelial cell proliferation. Several studies have indicated that the M2 macrophages
promote angiogenesis. The increase in M2 macrophages and decrease in proliferating cells in the current study suggests M2
macrophages promote endothelial cell migration and permeability rather than endothelial proliferation. Because endothelial
cells were not increased from control values at day 11 suggests the M2 macrophages alone cannot sustain an endothelial cell
response.
The day 5 decrease in myofibroblasts and subsequent increase in granulation tissue size suggests an influence of IL-1Ra on
wound contraction. Previous studies have reported an increase in mitogenic activity and differentiation of myofibroblasts after
IL-1 [beta] treatment. [31]-[33] Blocking IL-1 activation via IL-1Ra may thereby inhibit fibroblast proliferation and/or
differentiation to myofibroblasts. The early decrease in myofibroblasts and proliferating cells in the current study suggests
IL-1Ra bound to the fibroblast-localized IL-1 receptors and inhibited fibroblast proliferation and possibly fibroblast differentiation
into myofibroblasts. Myofibroblasts function in early wound contraction and later scar formation. The larger granulation tissue
size but insignificant change in type III collagen (a marker for scar formation) suggest that IL-1Ra inhibits myofibroblast-induced
wound contraction, rather than scar formation. Taken together, these results suggest that IL-1Ra influences granulation tissue
formation by modulating the myofibroblasts and M2-stimulated endothelial cell migration.
In contrast to a previous study that ablated macrophages during ligament healing [34], IL-1Ra administration had no negative
impact on the ligament mechanical properties. The trend (p = 0.125) for the IL-1Ra to increase in failure load in the current
study is, nevertheless, intriguing. Treatments were not specifically optimized for concentration requirements and half-life of
IL-1Ra in order to induce an improved mechanical outcome downstream. IL-1 is a potent cytokine and 100 fold or greater
levels of IL-1Ra over IL-1 are necessary to functionally inhibit the biological effects of IL-1 on target cells. [35] Additionally, the
half-life of IL-1Ra is only 6-8 hours. Without additional IL-1Ra treatments, the direct impact of IL-1Ra would rapidly diminish
and may not sufficiently affect downstream healing events. This interpretation explains both early and late results in this study,
i.e. enough IL-1Ra was administered to elicit a biological response attenuating some inflammatory events, but the dose and
half-life were not sufficient to improve "regenerative" healing and mechanical properties at day 11.
Overall, IL-1Ra altered the granulation tissue components of the healing ligament by stimulating an M2 macrophage and
endothelial cell response while inhibiting proliferation of myofibroblasts. IL-1Ra may then have therapeutic potential to favorably
alter the healing cascade. However, the single dose of IL-1Ra used in this study was not sufficient to maintain the regenerative
response at levels of statistical significance. Due to the transient influence of IL-1Ra on most of the healing components
assayed, a more sustained delivery of IL-1Ra should be explored.
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